Elina Asikanius

Elina Asikanius

UNVERIFIED PROFILE

Are you Elina Asikanius?   Register this Author

Register author
Elina Asikanius

Elina Asikanius

Publications by authors named "Elina Asikanius"

Are you Elina Asikanius?   Register this Author

13Publications

400Reads

21Profile Views

Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.

Haemophilia 2019 Mar 6;25(2):213-220. Epub 2019 Feb 6.

Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Parktown, Johannesburg, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hae.13655DOI Listing
March 2019

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.

N Engl J Med 2018 08;379(9):811-822

From the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.M.); Universitätsklinikum Bonn, Bonn, Germany (J.O.); Genentech, South San Francisco, CA (I.P.-P., J.I.A., G.G.L.); Louis Pradel University Hospital, Lyon, France (C.N.); F. Hoffmann-La Roche, Basel, Switzerland (M.N., C.S., C.D., E.A.); Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan (M.E.M.); the Hematology Department, Hospital Universitario La Paz, Autónoma University, Madrid (V.J.-Y.); the Department of Hematology and Medical Oncology, Emory School of Medicine, Atlanta (C.K.); Children's Hospital of Michigan, Detroit (M.U.C.); Instituto Costarricense de Investigaciones Científicas, San José, Costa Rica (W.B.); the Department of Pediatrics, Nara Medical University, Kashihara, Japan (M.S.); and the Washington Center for Bleeding Disorders at Bloodworks Northwest, Seattle (R.K.-J.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1803550
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1803550DOI Listing
August 2018

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

N Engl J Med 2017 08 10;377(9):809-818. Epub 2017 Jul 10.

From Universitätsklinikum Bonn, Bonn, Germany (J.O.); the Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and National Health Laboratory Service, Johannesburg (J.N.M.); Genentech, South San Francisco (B.K., N.V., G.G.L.), and Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles (G.Y.) - both in California; F. Hoffmann-La Roche, Basel, Switzerland (C.S., E.A.); Children's Hospital of Michigan, Detroit (M.U.C.); the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Foundation, Ospedale Maggiore Policlinico, Milan (E.S.); Bloodworks Northwest, Seattle (R.K.-J.); Louis Pradel Cardiology Hospital, University Claude Bernard, Lyon, France (C.N.); Georgetown University Medical Center, Washington, DC (C.K.); the Department of Disorders of Hemostasis and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland (J.W.); and the Department of Pediatrics, Nara Medical University, Kashihara, Japan (M.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1703068DOI Listing
August 2017

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

N Engl J Med 2014 Mar 8;370(12):1101-10. Epub 2014 Jan 8.

From the German CLL Study Group, Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne (V.G., K.F., A.E., B.E., C.M.W., K.-A.K., M.H.), the Department for Geriatric Medicine and Research, St. Marien Hospital and University of Cologne, Cologne (V.G.), Institute of Medical Statistics and Epidemiology, Technical University Munich, Munich (R.B.), Klinikum Schwabing, Munich (C.M.W.), private oncology practice, Dresden (T.I.), Medical Department II, University of Schleswig-Holstein, City Hospital Kiel, Kiel (M.R., M.K.), the Department of Internal Medicine III, Ulm University, Ulm (S.S., H.D.), and Cluster of Excellence "Cellular Stress Responses in Aging-Associated Diseases" (CECAD), University of Cologne, Cologne (M.H.) - all in Germany; Penza Regional Oncology Dispensary, Penza (T.C.), and Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod (O.S.) - both in Russia; Servicio De Hematologia, Hospital Universitario 12 De Octubre, Madrid (J.S.); Hôpital Haut Lévêque, Bordeaux, Pessac, France (M.-S.D.); the Department of Haematology, Monash Medical Centre, Clayton, Australia (S.O.); University of Calgary, Calgary, AB, Canada (C.J.O.); the Department of Immunology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands (A.W.L.); F. Hoffmann-La Roche, Basel, Switzerland (E.A.); F. Hoffmann-La Roche, Welwyn, United Kingdom (K.H.); and Genentech, South San Francisco, CA (M.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1313984DOI Listing
March 2014

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients.

Blood 2012 May 19;119(22):5126-32. Epub 2012 Mar 19.

Hospices Civils de Lyon, Hematologie, Université de Lyon, Unité Mixte de Recherche (UMR) 5239, Centre National de la Recherche Scientifique (CNRS), Pierre-Bénite, France.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2012-01-40
Publisher Site
http://dx.doi.org/10.1182/blood-2012-01-404368DOI Listing
May 2012